NASDAQ:LPTX Leap Therapeutics (LPTX) Stock Price, News & Analysis $0.49 -0.04 (-7.08%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.01 (+1.94%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Leap Therapeutics Stock (NASDAQ:LPTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Leap Therapeutics alerts:Sign Up Key Stats Today's Range$0.48▼$0.5250-Day Range$0.24▼$0.7652-Week Range$0.22▼$4.79Volume718,095 shsAverage Volume2.30 million shsMarket Capitalization$20.12 millionP/E RatioN/ADividend YieldN/APrice Target$3.38Consensus RatingReduce Company Overview Leap Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Leap’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion. DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Leap is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development. Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and trades on the NASDAQ under the ticker LPTX. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.AI Generated. May Contain Errors. Read More Leap Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreLPTX MarketRank™: Leap Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 440th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingLeap Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialLeap Therapeutics has a consensus price target of $3.38, representing about 593.0% upside from its current price of $0.49.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Leap Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Leap Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.82% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently decreased by 33.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.82% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently decreased by 33.62%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.69 News SentimentLeap Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Leap Therapeutics this week, compared to 1 article on an average week.Search Interest21 people have searched for LPTX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Leap Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.46% of the stock of Leap Therapeutics is held by institutions.Read more about Leap Therapeutics' insider trading history. Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LPTX Stock News HeadlinesLeap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025October 20 at 7:00 AM | prnewswire.comWall Street Zen Downgrades Leap Therapeutics (NASDAQ:LPTX) to Strong SellOctober 18 at 2:50 AM | americanbankingnews.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 21 at 2:00 AM | Porter & Company (Ad)Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyOctober 9, 2025 | finance.yahoo.comLeap Therapeutics Announces $58.88M Private PlacementOctober 8, 2025 | msn.comLeap Therapeutics stock soars after securing $58.9M investmentOctober 6, 2025 | investing.comLeap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyOctober 6, 2025 | prnewswire.comLeap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025September 25, 2025 | prnewswire.comSee More Headlines LPTX Stock Analysis - Frequently Asked Questions How have LPTX shares performed this year? Leap Therapeutics' stock was trading at $2.88 at the beginning of 2025. Since then, LPTX shares have decreased by 83.1% and is now trading at $0.4870. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.11. When did Leap Therapeutics' stock split? Shares of Leap Therapeutics reverse split on the morning of Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Leap Therapeutics' major shareholders? Top institutional shareholders of Leap Therapeutics include Simplify Asset Management Inc. (2.35%) and Key Client Fiduciary Advisors LLC (0.33%). View institutional ownership trends. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK). Company Calendar Last Earnings8/14/2025Today10/21/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPTX CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Leap Therapeutics$3.38 High Price Target$5.50 Low Price Target$1.25 Potential Upside/Downside+545.8%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-237.65% Return on Assets-155.38% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book0.57Miscellaneous Outstanding Shares41,440,000Free Float38,332,000Market Cap$21.66 million OptionableOptionable Beta-0.05 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:LPTX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.